Business Wire

GWI Appoints New Chief Technology Officer, Nick Dearden

Share

GWI, the global consumer research platform, today announced that it has appointed Nick Dearden as Chief Technology Officer, based in its UK headquarters in London.

Nick has over 25 years of experience in technology, with his grassroots as a developer. At GWI he will lead the engineering, IT, and security teams and will be responsible for the company's technology and data management strategy. His role is key to driving forward the company’s agenda to build technology that gives people clarity over their audience in the moment they need it.

Nick’s role will focus on the ongoing innovation, scaling, and automation of processes that underpin access to data representative of nearly 3 billion people across 50+ markets.

With simplification and ease of access to GWI data a key strategic driver, Nick will be responsible for identifying appropriate technology, such as AI, to define the technology strategy to achieve this. This will enable the company to automate and unlock powerful new features for customers by offering flexible solutions and tools that fit neatly into users' daily workflows.

CEO and Founder of GWI, Tom Smith, comments, “We help our customers understand consumers at speed. Our tech is about making it as easy as possible to surface important insights as part of their day-to-day. Some also want the ability to build their own tools and systems on top of our data - using our API and calculations engine. Nick’s proven expertise in making difficult to access data available in a unified platform will help us supercharge the innovation in our tech to deliver the best possible solutions to meet both these growing needs.”

Nick Dearden adds, “Joining the GWI team is an exciting opportunity with a fantastic product that has a strong market fit. It’s led by a superb team with crystal clarity over future potential for the business and its customers. The energy and passion is infectious, and there’s a clear opportunity for technology to play a key part in the future growth.

“My most recent experience of transforming OAG's product offering can be applied to GWI, and I am confident that developing the right technology to underpin the overall business strategy will unlock huge value.”

Prior to GWI, Nick was CTO at OAG where he defined and led the technology transformation to a new cloud data platform. Nick has also led multiple large technology functions, delivering products and services to a variety of industries with solutions ranging from video streaming to global travel platforms.

EDITORS NOTES:

About GWI

GWI is modernized consumer research – global, on-demand, and accessible to everyone, not just data experts. It’s a platform designed for companies that want fresh and insightful data about their consumers. Values, purchase journeys, media usage, social media habits - we cover it all. With data representative of nearly 3 billion people across 50+ countries, GWI has become the go-to for agencies, brands and media companies that want to know what really drives their audience to action. For more, visit www.gwi.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

The Hoffman Agency (UK)
gwi@hoffman.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Announces Grant of Employment Inducement Awards1.3.2024 22:15:00 CET | Press release

IFF (NYSE: IFF) today announced the grant of employment inducement awards to J. Erik Fyrwald, IFF Chief Executive Officer and member of the Board of Directors. The Company's Board of Directors approved the employment inducement awards on Jan. 9, 2024, with a grant date of March 1, 2024, as a material inducement to enter into an offer of employment in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08 that requires shareholder approval of equity-based compensation plans. Listing Rule 303A.08 requires the public announcement of such an award. The inducement awards will consist of (i) a target award of 68,750 performance share units (with a maximum award of 171,875 performance share units), subject to meeting the applicable performance targets set forth in the award agreement, and (ii) 56,250 restricted stock units, 100% of which will vest on the three-year anniversary of the grant date, for a maximum potential combined payout of 228,125

Whitehorse Liquidity Partners Recognized by Private Equity International’s 2023 Awards1.3.2024 16:30:00 CET | Press release

Whitehorse Liquidity Partners (together with its advisory affiliates, “Whitehorse”), a specialized investment manager focused on providing structured liquidity solutions to the alternative asset class, is pleased to announce recognition from Private Equity International (PEI) in the 2023 PEI Awards. Whitehorse placed third in the Secondaries Firm of the Year in the Americas category alongside Blackstone Strategic Partners and HarbourVest Partners and was voted Firm of the Year in Canada. “We are honoured to have been recognized again in two categories by the PEI Awards,” said Yann Robard, Managing Partner of Whitehorse. “For the fourth time among the top three Secondaries Firm of the Year in the Americas category (2018, 2020, 2022 and 2023) and the sixth time among the top three in the Firm of the Year in Canada category (2017, 2018, 2020, 2021, 2022 and 2023). You often hear us say that big is beautiful, growth is good and scale matters. Our scale has enabled us, not disrupted us. We

Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign1.3.2024 14:30:00 CET | Press release

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin KleinETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITYfragrance portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301420936/en/ Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Business Wire) Shot by Mert Alas, the campaign offers a fresh and impactful take on ETERNITY’s timeless dream of eternal love, capturing Idris and Sabrina in moments of intimacy set to a bespoke cover of “Fever” by FKA twigs. The striking campaign imagery is inspired by profound connection and the essence of desire, paying tribute to ETERNITY’s legacy of sensuality by partnerin

Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV1.3.2024 13:35:00 CET | Press release

The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/ Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire) With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprie

GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta1.3.2024 09:37:00 CET | Press release

GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye